1-2 of 2
clarity trial
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Peter Hillmen, MBChB, PhD, Talha Munir, Andy Rawstron, PhD, Kristian Brock, MSc, BSc, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Rebecca Bishop, BSc, Christopher Fegan, MD, Donald Macdonald, Alison McCaig, PhD, Anna Schuh, MD PhD, Andrew Pettitt, FRCPath, PhD, John G. Gribben, MDDSc FMedSci, Stephen Devereux, FRCP, FRCPath, PhD, Adrian Bloor, Christopher P Fox, MBChB PhD, Francesco Forconi, MD DM, PhD FRCPath
Journal: Blood
Blood (2017) 130 (Supplement 1): 428.
https://doi.org/10.1182/blood.V130.Suppl_1.428.428
Published: 2017
Journal Articles

Molecular Mechanisms of Ibrutinib Resistance: Defining a Logical Approach to Improving Targeted Therapy in CLL

Sara MK Farag, MBBCh, MSc in MDcal sciences, Darren Newton, PhD, Gina Doody, Associate Professor, Molecular Immunology, Lotfy Abdelnaby Mahmoud, Professor of Haematology, Manal Ibrahim Fouda, Professor of Haematology, Doaa Mahmoud El Ghannam, Professor of Clinical Pathology, Peter Hillmen
Journal: Blood
Blood (2016) 128 (22): 2046.
https://doi.org/10.1182/blood.V128.22.2046.2046
Published: 2016